Facility
Hybio Pharmaceutical - Shenzhen, Guangdong China
Operated by Hybio Pharmaceutical Co., Ltd →CN
Chinese peptide manufacturing for GLP-1 APIs; semaglutide commercial manufacturing agreement signed Aug 2025; supplies emerging market biosimilars
0
Inputs produced
0
Goods downstream
0
Incidents on record
0
Stories